



#

There were no keywords in this range.

A

acral melanoma	B051
Acute myeloid leukemia	B010
adagrasib	A016
adaptive signaling	B035
Alcea rosea compounds	A004
Allelic imbalance	A050
alphascreen	A039
Angiogenesis, Thrombospondin	B041
antibody-derivatived compounds	A039
anti-PD-L1 therapy	B029
Apoptosis	A003
appendix cancer	B024
Aurora Kinase A	A013
AXL inhibition	A012
AXL inhibitor	A015

B

Blood-brain barrier	B008
branched actin morphogenesis	A030
Breast cancer	A040
BRET; BBO-11534 inhibitor; state 1 - state 2	A047

C

cancer associated fibroblasts	B025
Cancer immunotherapy	A052
chemoresistance	A023
chemotherapy	A011
Chromosomal instability	A013
Colorectal cancer	A003, B043
Colorectal Cancer	B021
Combination chemotherapies	A010
Combination efficacy	A015



Combination strategies	B004
combination therapies	A033
Combination therapy	A012, A018
Combination Therapy	B040
Combination therapy	A019
Combinations and RASi-Resistance	B045
combinatorial crispr screens	A014
Combined therapy	A009
CRAF	A029
CRISPR screen	A008
cryo-EM	A048
Cryptic pocket	A046
CYPA	B033

D

daraxonrasib	A016, B026
Daraxonrasib	A040, B008
Deep Mutational Scanning	A045
degradation	A025
disulfide tethering library screening	B006
Drug combinations	A020
drug resistance	B048, B049
Drug resistance	B021, B028
Drug resistance	B026

E

epigenetic reprogramming	A027
Epigenetic reprogramming	B018
ERK	A026
ERK inhibitor combination	A005
extracellular matrix drug resistance	B025

F

Ferroptosis	B013
focal adhesion kinase	A022
Functional precision medicine	A020
FYN	B036



G

G12C	B037
G13C	A011
GAP	A049
GEF	A049
gemcitabine nab-paclitaxel	A017
Generative AI	A036
genetic interactions, KRAS mutant cancer cells	A014
genomic	B046
Genotype	B042
GFH375	B007
GJB3, Cystine Starvation, SLC7A11	A031
Gynecologic cancer	A038

H

There were no keywords in this range.

I

ICPN	A041
Immune checkpoint blockade	A023
immune checkpoint inhibitor	B029
immune microenvironment	A033
immunosuppression	A037
Immunotherapy	A032
In vivo CRISPRa screening	A012
inflammation	B034
Insulin-like growth factor 2 mRNA binding protein 2	A001
Intracholecystic Papillary Neoplasm	A041

J

There were no keywords in this range.

K

KRAS inhibitors	A022
KEAP1-mutant lung adenocarcinoma	B013
Kinase	A026



KRAS	A003, A008, A025, A045, B003, B019, B020, B028, B031, B044, B047
KRAS amplification	A044
KRAS Amplification	A032
KRAS cryptic pockets	B006
KRAS dependent cancer	B041
KRAS G12C Resistance	A005
KRAS G12Ci resistance	B018
KRAS G12D	A038
KRAS G12D inhibitor	B007
KRAS G12V	A006
KRAS GTP Levels	A049
KRAS inhibition	A050, B013, B015, B024
KRAS inhibitor	A002, A015
KRAS inhibitor resistance	B030
KRAS mutation	A027
KRAS Switch-II inhibitors	B002
KRAS, SOS, Translation initiation factor eIF2B	B001
KRASG12C resistance	B043
KRASG12D, KRASG12V, KRASG12R	B043
KRAS-mutant colorectal cancer	A004
L	
ligand discovery	B006
lineage plasticity	B038
lineage reprogramming	B034
LKB1	B035
LNK (SH2B3)	B050
lung cancer	A033, A037
LZTR1	A043
M	
MAPK, BRAF,	B016
MD simulation	A024
MEK inhibitor	B030
MEK1/2	A029
Menin	B021



mitochondria, ChIP-seq, apoptosis	B017
Mitogen-activated Protein Kinase, Glycosphingolipid biosynthesis, KRAS4B	B001
immunoprecipitation	A047
Molecularly targeted therapies	A010
MPN	B040
mRNA translation, lung adenocarcinoma, tumorigenesis	B001
MRTX1133	A011
Multiple myeloma	A018
Mutant dosage	A050
mutant KRAS	A035
mutant KRAS; NMR structure; HSQC	A047
myeloid-derived suppressor cells	A034
myeloma	B027

N

nanobody	A046
narmafotinib	A022
Network pharmacology	A024
NFAT5	B019
Non-genetic drug resistance	A028
Non-small cell lung cancer	B023
ΔNp63, mutant-TP53, AMG510, drug-resistance	B017
NRAS-mutant melanoma	A028, B045, B050

O

oncogene hyperactivation lethality	A008
oncogenic KRAS	A030, B023
oncogenic RAS molecular signaling	A030

P

Pancreas cancer	B015
Pancreatic Adenocarcinoma	A007
pancreatic cancer	A035, B014
Pancreatic cancer	A020
Pancreatic Cancer	A026



Pancreatic ductal adenocarcinoma	A027
Pancreatic tumorigenesis	B043
panKRAS	A039
pan-Ras inhibition	B004
pan-RAS inhibitor	B014
Pan-RAS inhibitors	A051
pan-TEAD	A006
Patient-derived organoid	A002
PDAC	A009, B036
pediatric cancer	B049
Pharmacokinetics	B008
Phosphodiesterase 10	A034
Phosphorylation	A043
PI3K	B028
PIKfyve	A019
precision oncology	B003
Preclinical studies for pancreatic cancer	A010
PROTAC	A025
Proteasome-mediated degradation	B047
Protein degradation	A029
protein engineering	B048
Protein Phosphatases, MAPK inhibitors, Experimental; Therapeutics	B012
proteomics	B011
pyroptosis	B051

Q

There were no keywords in this range.

R

RAF	A046
RAF1	B026
Rare RAS mutants	A051
Ras	A052, B042
RAS	A007, A043, A048, B033, B036, B046
RAS G12C; Topoisomerase II; sotorasib	A021
Ras inhibition	B023, B029



RAS inhibitor	A023
RAS inhibitor combinations	A017
Ras inhibitor resistance	B027
RAS inhibitors	B037, B051
Ras isoform	B048
RAS mutations. Pancreatic cancer. Molecular subtypes. prognostic	A042
RAS oncogenes	B003
RAS signaling	A018
RAS signaling heterogeneity	B043
RAS signaling,	A034
RAS(ON) inhibitors	A028
receptor tyrosine kinase (RTK)	A007
Rectal cancer	A002
resistance	A006, B011, B019, B033
Resistance	A032, A052, B014, B020, B031, B040
Resistance mechanisms	B015
Resistance, Colorectal, RMC6236	B016
rhabdomyosarcoma	B046, B049
RNA binding protein	A001
RRAS	A051
RTK–RAS signaling	B010
Rutin	A024
S	
S6K2 and lethal lipid peroxidation	B045
screen	B027
Secondary AML	B004
secondary resistance mutations	B002
Senescence	A040
SHOC2	A048
silent mutations	B044
small molecule inhibitors	B031
sotorasib	A037
Sotorasib, pancreatic, breast	B016
STK11	A041
Stress MAPK	B043



structure and function	B002
Structure-Function	A045
Synergistic effect	A009
synergy	A016
synthetic lethality	A014

T

T cell engager	A036
Targeting cell states	A017
TCR	A036
TCR-T cell therapy	A035
therapeutic resistance	B035
Therapeutic resistance	B042
Therapeutic Resistance	A001
therapy resistance	B034, B038
TIMP-1	B041
transcriptomics	B011
translational modeling	B037
Tumor immune microenvironment (TIME)	B050
tumor microenvironment	B025
Tumor microenvironment	B047
Tumor Microenvironment	B024

U

There were no keywords in this range.

V


VP-16 (etoposide); lung cancer	A021
VS-7375	B007

W

Whole exome sequencing	B010
wild-type KRAS	B044
window of opportunity trial	B030

X

There were no keywords in this range.



AACR Special Conference in Cancer Research

RAS ONCOGENESIS AND THERAPEUTICS

March 5-8, 2026 | Los Angeles, CA

AACR

American Association
for Cancer Research®

2509018F

Y

There were no keywords in this range.

Z

There were no keywords in this range.